Thymosin beta 4 speeds corneal wound healing and decreases inflammation in the clinical setting — VialBase Research

Summary

Review covering the clinical development of RGN-259, a Tβ4-based eye drop formulation for corneal wound healing. This represents the most advanced clinical application of thymosin beta-4, with data from clinical trials in neurotrophic keratopathy and dry eye disease. Provides the strongest clinical evidence supporting Tβ4 healing properties.

Key Findings

• RGN-259 (topical Tβ4) progressed through phase 2 clinical trials for corneal healing
• Demonstrated efficacy in neurotrophic keratopathy (persistent corneal defects)
• Improved corneal wound healing rates in clinical settings
• Anti-inflammatory effects complemented wound healing in ocular surface disease
• Well-tolerated in clinical trials with good safety profile
• Represents the closest any Tβ4 product has come to regulatory approval

Methodology

Review synthesizing clinical trial results from the RGN-259 development program, including phase 1/2 and phase 2 studies in corneal wound healing and neurotrophic keratopathy. Covers clinical endpoints, safety data, and mechanism of action.

Limitations

• Ophthalmological application — not directly applicable to musculoskeletal or systemic use
• Topical formulation — different from injectable TB-500
• Full-length Tβ4, not the TB-500 fragment
• Clinical program has faced regulatory delays
• Limited to corneal healing — cannot extrapolate to other tissue types

Relevance to Content

Important because it’s the closest to clinical validation for any Tβ4 product. Strengthens the evidence base for TB-500 content by showing that the parent molecule has advanced clinical development. Content should note the tissue-type and formulation differences between RGN-259 and injectable TB-500.

See Also

• Parent compound: TB-500